What is this study trying to find out about COPD?

This study aims to learn more about COPD and lung cancer screening in people undergoing lung cancer screening. Researchers want to see if lung cancer screening can help identify COPD cases and understand symptom burden, lung function, imaging, and blood markers. The study is led by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Who may be eligible for this COPD clinical trial?

Adults aged 50 to 80 years who currently or formerly smoked at least 20 pack-years may be eligible. Participants should have a clinical lung cancer screening CT scan within the past year and either a prior COPD diagnosis, lung function tests showing COPD, or lung scan evidence of COPD. People with severe asthma or other lung diseases may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this COPD clinical trial?

Study-related care, including all study procedures and trial visits, is provided at no cost. Participants may have personal travel expenses which are not guaranteed to be covered. Participants should plan for any travel costs they might incur.

Actively Recruiting

Age: 50Years - 80Years

All Genders

ID06974981

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management COPD in LCS Registry

Led by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Updated on 2026-03-03

420

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to better understand chronic obstructive pulmonary disease COPD and lung cancer screening outcomes in individuals undergoing lung cancer screening. It focuses on identifying cases of COPD using data from lung cancer screening programs and assessing factors like symptoms, lung function, imaging, and blood markers. The study is observational and plans to enroll approximately 420 participants over two years to evaluate the feasibility of using lung cancer screening to identify COPD cases. Participants will have clinical data collected at the start and again 12 to 15 months later. Initial procedures include a blood draw for a complete blood count if not done recently, pulmonary function testing including spirometry and a six-minute walk test if not done within the last year, and a low-dose CT scan for lung cancer screening. Participants also complete several questionnaires about respiratory symptoms, medication use, and smoke exposure. Those needing pulmonary function tests will have a separate visit to complete these procedures. Throughout the study, participants will be followed for at least 15 months to monitor adherence to annual lung cancer screening with repeat CT scans. The study collects data on COPD diagnosis, participant enrollment rates, compliance with study procedures, and retention over two years. This process includes surveys, lung function tests, imaging, blood work, and tracking lung cancer screening adherence to better understand COPD in this group.

CONDITIONS

Brief Title

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry

Who Can Participate

Age: 50Years - 80Years

All Genders

Eligibility Criteria

You may qualify if you...

Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at least 20 pack-years of smoking history at the time of consent
Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies including interventional trials
Ability to tolerate study procedures
Ability to provide informed consent
Clinical lung cancer screening CT performed at the University of Michigan within the last year
Meets at least one of the following: prior COPD diagnosis in medical records, prior pulmonary function tests showing COPD, or lung cancer screening CT scan showing lung abnormalities consistent with COPD

You will not qualify if you...

Presence of a respiratory condition other than COPD or asthma, or other conditions likely causing respiratory symptoms
Severe asthma defined by current high-level asthma medication use or frequent healthcare visits for asthma in past 12 months
Participation in a blinded therapeutic trial
Active pregnancy; birth control documentation required for pre-menopausal women
Cognitive dysfunction preventing completion of study procedures
Body mass index over 35 kg/m2 due to effects on CT scan quality
Current illicit substance abuse including cannabis smoking
Illness expected to cause death within 3 years
Presence of implanted metallic devices or prosthesis above the waist affecting CT scan quality
History of thoracic radiation or lung surgery involving lung tissue removal
Recent acute COPD exacerbation or recent use of acute antibiotics or steroids within 30 days; certain chronic medications allowed as specified in the criteria

Research Team

Julie Barta, MD, ATSF

Yolanda Kry, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here